Kronos Bio
- Company typePrivate
- Founded2017
- HeadquartersSan Mateo, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Kronos Bio firmographics
Firmographics- Name
- Kronos Bio
- Website
- https://kronosbio.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Where Kronos Bio is headquartered
LocationHeadquarters
- HQ city
- San Mateo
- HQ country
- United States
- HQ region
- North America
Markets served
Kronos Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Others
Revenue model
- Drug Development Pipeline: Pre-commercial biopharmaceutical company developing lanraplenib through clinical trials. Revenue generation would occur upon FDA approval and commercialization, likely through pharmaceutical product sales or potential licensing/partnership arrangements.
Kronos Bio product offering
Product offeringCore offering
Kronos Bio is a clinical-stage biopharmaceutical company developing first-in-class therapies that modulate historically recalcitrant cancer targets. Its lead asset, lanraplenib, is a proprietary SYK (spleen tyrosine kinase) inhibitor being advanced in clinical trials for patients with relapsed/refractory acute myeloid leukemia (AML). The company has no commercialized products and focuses entirely on research, clinical development, and eventual commercialization or out-licensing of its drug candidate.
Product overview
Kronos Bio is a pharmaceutical company developing lanraplenib, a SYK inhibitor drug candidate in clinical trials for relapsed/refractory acute myeloid leukemia (AML). The company's product pipeline consists of this single drug candidate representing a therapeutic approach targeting the SYK signaling pathway.
Differentiator
Problem solved
Functional benefit
Products and services
- Lanraplenib
Companies that use Kronos Bio
Customer profileSegments1 record
Ideal customer profiles1 record
Kronos Bio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Kronos Bio partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights3 records
Kronos Bio competitors and assessment
Company assessmentBroad incumbents
- AstraZeneca: Global pharmaceutical company with active AML programs, including CALQUENCE (acalabrutinib) in hematologic malignancies and investigational AML assets. Comparable as a broad incumbent with overlapping oncology development and significant commercial reach.
- AbbVie: Large pharmaceutical company with venetoclax (Venclexta), a leading Bcl-2 inhibitor approved for AML in combination regimens. Represents the established standard-of-care competitor that Kronos Bio's lanraplenib would need to differentiate against.
- Bristol-Myers Squibb: Major pharmaceutical company with a substantial AML franchise including azacitidine-based combinations and an active pipeline of hematology assets. Comparable as a broad incumbent with overlapping AML development and commercialization capabilities.
- Gilead Sciences: Large biopharmaceutical company with magrolimab, an anti-CD47 antibody in development for AML and MDS, representing a novel immuno-oncology approach to hematologic malignancies. Comparable as a broad incumbent investing heavily in next-generation AML therapeutics.
- Astellas Pharma: Global pharmaceutical company that commercializes gilteritinib (Xospata), an FLT3 inhibitor approved for relapsed/refractory AML. Represents another entrenched large-pharma competitor in the same AML indication.
Direct peers
- Syros Pharmaceuticals: Clinical-stage biopharmaceutical company focused on hematologic malignancies and AML, developing novel small molecule therapies targeting gene expression. Highly comparable to Kronos Bio as a similarly-sized, similarly-staged oncology therapeutics developer with hematology pipeline assets.
- Kura Oncology: Clinical-stage precision oncology company developing small molecule therapeutics for hematologic malignancies and solid tumors. Comparable to Kronos Bio as a similarly-staged small-cap oncology developer with targeted small molecule assets.
- Rigel Pharmaceuticals: Commercial and clinical-stage company that developed fostamatinib, a SYK inhibitor approved for immune thrombocytopenia. Directly comparable to Kronos Bio through shared SYK kinase pharmacology and small molecule hematology/oncology focus.
- Curis: Clinical-stage biotechnology company developing targeted therapeutics for hematologic malignancies and solid tumors. Comparable to Kronos Bio as a similarly-staged clinical developer focused on oncology.
Emerging players
- Aprea Therapeutics: Clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics that target DNA damage response pathways. Comparable to Kronos Bio as a small-cap, clinical-stage oncology developer with single-asset or focused pipeline exposure.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights5 records
Customer concentration
Kronos Bio social profiles
Digital presenceKronos Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kronos Bio leadership team
Management profileNumber of profiles
Profiles1 record
Kronos Bio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kronos Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kronos Bio
What does Kronos Bio do?
Kronos Bio is a clinical-stage biopharmaceutical company developing first-in-class therapies that modulate historically recalcitrant cancer targets. Its lead asset, lanraplenib, is a proprietary SYK (spleen tyrosine kinase) inhibitor being advanced in clinical trials for patients with relapsed/refractory acute myeloid leukemia (AML). The company has no commercialized products and focuses entirely on research, clinical development, and eventual commercialization or out-licensing of its drug candidate.
When was Kronos Bio founded?
Kronos Bio was founded in 2017. It employs 51 to 100 people.
Where is Kronos Bio based?
Kronos Bio is headquartered in San Mateo, United States, in the North America region.
How does Kronos Bio make money?
One revenue line is on record: drug Development Pipeline.
Who are Kronos Bio's main competitors?
Broad incumbents on record are AstraZeneca, AbbVie, Bristol-Myers Squibb, Gilead Sciences and Astellas Pharma. Direct peers are Syros Pharmaceuticals, Kura Oncology, Rigel Pharmaceuticals and Curis. Aprea Therapeutics is listed as an emerging player.
Does Kronos Bio have an API?
No public API is recorded for Kronos Bio.